Published 09/27/2024 11:13:59 a.m.

Acumen Pharmaceuticals Extends Alzheimer’s Collaboration with Lonza

Summary by contractpharma.com

Aims to enable the potential future commercial launch of sabirnetug (ACU193).

0 Articles

All

Left

Center

Right

contractpharma.com

Acumen Pharmaceuticals Extends Alzheimer’s Collaboration with Lonza

Aims to enable the potential future commercial launch of sabirnetug (ACU193).

09/27/2024 1:48:00 p.m.

Read Full Article

Pharmaceutical Business review

Acumen Pharmaceuticals extends collaboration with Lonza for sabirnetug

Sabirnetug is a humanised monoclonal antibody that has shown selective target engagement with toxic soluble amyloid beta (Aβ) oligomers in patients with AD. The partnership between Acumen and The post Acumen Pharmaceuticals extends collaboration with Lonza for sabirnetug appeared first on Pharmaceutical Business review.

09/27/2024 11:13:59 a.m.

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center0Last Updated09/27/2024 6:05:54 p.m.Bias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Acumen Pharmaceuticals Extends Alzheimer’s Collaboration with Lonza

0 Articles

0 Articles

Acumen Pharmaceuticals Extends Alzheimer’s Collaboration with Lonza

Acumen Pharmaceuticals Extends Alzheimer’s Collaboration with Lonza

Acumen Pharmaceuticals extends collaboration with Lonza for sabirnetug

Acumen Pharmaceuticals extends collaboration with Lonza for sabirnetug

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics